{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:42:40Z","timestamp":1775634160818,"version":"3.50.1"},"reference-count":30,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The utility of a midcycle bone marrow biopsy (BMB) for early assessment of response in patients with acute myeloid leukemia (AML) after intensive chemotherapy (IC) induction is contested. Even when challenged, there is little consideration as to the possibility of different response dynamics among genetically defined subgroups. Clinical observations led to the hypothesis that patients with AML and mutations in IDH2-R172 (R172-m) exhibit particularly slow blast reduction after IC induction. The purpose of this study was to analyze response kinetics of patients with R172-m to IC and compare the dynamics to patients with AML and IDH2-R140 mutations (R140-m). A retrospective single-center analysis was conducted among patients with newly diagnosed IDH2-mutated AML who received IC induction. Dynamics of blast reduction were compared and correlated with outcomes. A total of 52 patients were identified; 33 with R140-m and 19 with R172-m. Patients with R172-m had significantly higher midcycle BMB median blast count (70% vs 5%; P &amp;lt; .001), and their BMBs were slightly more cellular (P = .045). Among the R140-m, 58% had \u22645% blasts vs 0 of the R172-m. Furthermore, it took significantly longer for patients with R172-m to achieve blast clearance (\u22645% blasts in BMB) compared to those with R140-m (P = .017). However, there was no difference in overall survival between the 2 groups, and outcomes were similar and favorable. This type of slow blast reduction has only previously been described in patients with acute promyelocytic leukemia. These findings suggest judicial application of reinduction strategies in this subgroup and warrant further investigation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015324","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T15:51:06Z","timestamp":1744127466000},"page":"3213-3222","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Patients with AML and an <i>IDH2-R172<\/i> mutation exhibit a unique initial response to intensive chemotherapy induction"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8504-2773","authenticated-orcid":false,"given":"Meira","family":"Yisraeli Salman","sequence":"first","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4731-8537","authenticated-orcid":false,"given":"Alexander R.","family":"Terry","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-8493","authenticated-orcid":false,"given":"Andriy","family":"Derkach","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Nemirovsky","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4504-398X","authenticated-orcid":false,"given":"Kuo-Kai","family":"Chin","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-8006","authenticated-orcid":false,"given":"Yannis K.","family":"Valtis","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leora","family":"Boussi","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Spivey","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8586-8500","authenticated-orcid":false,"given":"Wenbin","family":"Xiao","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Famulare","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Ciervo","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob M.","family":"Rowe","sequence":"additional","affiliation":[{"name":"2Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"3Department of Hematology and BMT, Rambam Health Care Campus and Technion, Israel Institute of Technology, Haifa, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"1Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"2025070811215517800_bib1","volume-title":"Acute Myeloid Leukemia (Version 3.2024)","year":"2024"},{"issue":"suppl 1","key":"2025070811215517800_bib2","doi-asserted-by":"crossref","first-page":"8929","DOI":"10.1182\/blood-2022-164963","article-title":"Time to abandon the day 14 bone marrow biopsy in acute myeloid leukemia patients receiving induction chemotherapy","volume":"140","author":"Branham","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2025070811215517800_bib3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/ajh.24818","article-title":"Day 14 bone marrow examination in the management of acute myeloid leukemia","volume":"92","author":"Terry","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"2025070811215517800_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2012.09.016","article-title":"Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia","volume":"37","author":"Morris","year":"2013","journal-title":"Leuk Res"},{"issue":"10","key":"2025070811215517800_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2025070811215517800_bib6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1186\/s12885-023-11034-7","article-title":"Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"23","author":"Qin","year":"2023","journal-title":"BMC Cancer"},{"issue":"3","key":"2025070811215517800_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"7274","key":"2025070811215517800_bib8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"6","key":"2025070811215517800_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"7390","key":"2025070811215517800_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/nature10860","article-title":"IDH mutation impairs histone demethylation and results in a block to cell differentiation","volume":"483","author":"Lu","year":"2012","journal-title":"Nature"},{"issue":"1","key":"2025070811215517800_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"4","key":"2025070811215517800_bib12","doi-asserted-by":"crossref","first-page":"e2208176120","DOI":"10.1073\/pnas.2208176120","article-title":"Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells","volume":"120","author":"Fortin","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2025070811215517800_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood"},{"issue":"suppl 1","key":"2025070811215517800_bib14","first-page":"2682","article-title":"IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies","volume":"130","author":"Meggendorfer","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2025070811215517800_bib15","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025070811215517800_bib16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med"},{"issue":"23","key":"2025070811215517800_bib17","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"2025070811215517800_bib18","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1074\/jbc.M112.435495","article-title":"The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization","volume":"288","author":"Ward","year":"2013","journal-title":"J Biol Chem"},{"issue":"12","key":"2025070811215517800_bib19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2025070811215517800_bib30","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025070811215517800_bib20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2025070811215517800_bib21","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood-2002-02-0532","article-title":"Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial","volume":"101","author":"Kern","year":"2003","journal-title":"Blood"},{"issue":"1","key":"2025070811215517800_bib22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3324\/haematol.2013.091819","article-title":"Prognostic impact of day 15 blast clearance in risk-adapted remission induction chemotherapy for younger patients with acute myeloid leukemia: long-term results of the multicenter prospective LAM-2001 trial by the GOELAMS study group","volume":"99","author":"Bertoli","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"2025070811215517800_bib23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.24.00235","article-title":"Single or double induction with 7 + 3 containing standard or high-dose daunorubicin for newly diagnosed AML: the randomized DaunoDouble trial by the Study Alliance Leukemia","volume":"43","author":"R\u00f6llig","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025070811215517800_bib24","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/ajh.24207","article-title":"Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the \u201c3 + 7\u201d induction regimen for acute myeloid leukemia","volume":"90","author":"Ofran","year":"2015","journal-title":"Am J Hematol"},{"issue":"8","key":"2025070811215517800_bib25","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1182\/bloodadvances.2020003685","article-title":"A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML","volume":"5","author":"Mason","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2025070811215517800_bib26","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1200\/JCO.1985.3.6.793","article-title":"A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia","volume":"3","author":"Kantarjian","year":"1985","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025070811215517800_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \"retinoic acid syndrome\" in acute promyelocytic leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann Intern Med"},{"issue":"19","key":"2025070811215517800_bib28","doi-asserted-by":"crossref","first-page":"4767","DOI":"10.3390\/cancers15194767","article-title":"Differentiation syndrome in acute leukemia: APL and beyond","volume":"15","author":"Woods","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"2025070811215517800_bib29","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3324\/haematol.2021.279134","article-title":"Acute myeloid leukemia: negative prognostic impact of early blast persistence can be in part overcome by a later remission prior to post-induction therapy","volume":"107","author":"Ihlow","year":"2022","journal-title":"Haematologica"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3213\/2382206\/blooda_adv-2024-015324-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/13\/3213\/2382206\/blooda_adv-2024-015324-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,8]],"date-time":"2025-07-08T15:22:09Z","timestamp":1751988129000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/13\/3213\/536601\/Patients-with-AML-and-an-IDH2-R172-mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,26]]},"references-count":30,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2025,7,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015324","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,8]]},"published":{"date-parts":[[2025,6,26]]}}}